WINT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	28 356.00
Średni wolumen	15 071.00
Kapitalizacja rynkowa	2.67M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $-0.940 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0.0740 (1.35%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-27	Fraser Craig	Buy	2 500	Common Stock
2023-09-26	Fraser Craig	Buy	2 500	Common Stock
2023-08-24	Mcandrew Jamie	Sell	0	Common Stock
2023-08-24	Mcandrew Jamie	Buy	0	Common Stock
2023-08-24	Mcandrew Jamie	Sell	220	Employee Stock Option (Right to Buy)

INSIDER POWER
36.21
Last 96 transactions
Buy: 7 918 771 \| Sell: 11 081 644

Windtree Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
MIGI	0.974
NAOV	0.968
VYNE	0.941
SNGX	0.922
XM	0.921
STX	0.917
DRNA	0.912
SHIP	0.909
TREE	0.903
SUMO	0.901

10 Najbardziej negatywne korelacje
GMII	-0.909
XPDI	-0.892
WASH	-0.87
ATSG	-0.86
AKAM	-0.859
EAR	-0.854
CSGP	-0.854
CCSI	-0.849
AFYA	-0.848
ALHC	-0.847

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Windtree Therapeutics Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-82 000.00 (0.00 %)
EPS:	$-94.23

FY	2023
Przychody:	$0
Zysk brutto:	$-82 000.00 (0.00 %)
EPS:	$-94.23

FY	2022
Przychody:	$0
Zysk brutto:	$-1.06M (0.00 %)
EPS:	$-62.23

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.73

Financial Reports:

No articles found.

Windtree Therapeutics Inc

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.